Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?
G. Petralli,A. Salvati,S. Cappelli,L. Surace,G. Ricco,P. Colombatto,A. Solini,M.R. Brunetto
DOI: https://doi.org/10.1016/j.dld.2024.01.084
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction and Aim Therapeutic options for MASLD burden in T2D patients are scanty. GLP1-receptor agonists (GLP1-ra) are clearly indicated for T2D treatment and Semaglutide was shown to induce the steatohepatitis resolution at high daily dosage. In consecutive MASLD- GLP1-ra naïve diabetic patients we studied the impact on liver disease of Semaglutide introduction for glycemic control indication using non-invasive surrogate markers of liver steatosis and fibro-inflammation. Methods In 62 consecutive overweight/obese T2D pts with MASLD (age 61.4 ± 11.3yrs, females 32%, BMI 31.4 ± 5.0kg/m2), anthropometric, bio-humoral and transient elastography (TE) data were collected before (t0) and after 6.4 (6.1-6.6) months (t1) from the 1st injective/oral Semaglutide prescription. GIP, GLP1, Glucagon, Insulin, AST, ALT and GGT were measured in t0-t1 serum samples. FibroScan CAP and liver stiffness (LS) were used as non-invasive markers of liver steatosis and fibro-inflammation involvement (proxy), respectively. Results BMI (-1.4 ± 0.2kg/m2), Waist Circumference (-3 ± 1cm), AST (-10 ± 3UI/L), ALT (-18 ± 5UI/L) GGT (-33 ± 15UI/L), glycol-metabolic parameters [fasting glucose (-40 ± 6mg/dl) and glycated hemoglobin (-12 ± 1mmol/mol)], CAP (-25 ± 8dB/m), and LS (-0.8 ± 0.4kPa) t0-t1 reductions were significant (p<0.006), while GLP1 (+95.9pM, p<0.0001) increased. Variations of serum ALT and GGT levels associated with glycated hemoglobin reduction (r=0.340, p=0.0196 and r=0.368, p=0.0210, respectively), but not with change in serum concentration of incretin hormones. CAP declined in association with BMI decline (r=0.391, p=0.0035) and GLP1 increase (r=-0.415, p=0.0251). In a multivariate model adjusted for all above mentioned variations, only the GLP1 increase was associated with CAP reduction (p=0.0468). Conclusion Semaglutide treatment for T2D in MASLD pts associates with a significant decline of non-invasive liver steatosis and fibro-inflammation proxy. While glycemic optimization correlated with a reduction of transaminases, an independent effect of GLP1 increase was associated with a reduction of the steatosis index.
gastroenterology & hepatology